Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Loans - Loss Allowance: 2012-2024

Historic Loans - Loss Allowance for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2024 value amounting to -$414.8 million.

  • RedHill Biopharma's Loans - Loss Allowance rose 2966.94% to $22.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.7 million, marking a year-over-year increase of 2966.94%. This contributed to the annual value of -$414.8 million for FY2024, which is 201.73% down from last year.
  • RedHill Biopharma's Loans - Loss Allowance amounted to -$414.8 million in FY2024, which was down 201.73% from $407.7 million recorded in FY2023.
  • RedHill Biopharma's 5-year Loans - Loss Allowance high stood at $433.9 million for FY2022, and its period low was -$414.8 million during FY2024.
  • For the 3-year period, RedHill Biopharma's Loans - Loss Allowance averaged around $142.3 million, with its median value being $407.7 million (2023).
  • Data for RedHill Biopharma's Loans - Loss Allowance shows a maximum YoY slumped of 201.73% (in 2024) over the last 5 years.
  • RedHill Biopharma's Loans - Loss Allowance (Yearly) stood at $433.9 million in 2022, then fell by 6.02% to $407.7 million in 2023, then slumped by 201.73% to -$414.8 million in 2024.